Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline)

Medical Clinics of North America

Volumn 95, Issue 4, 2011, Pages 761-791

  Zuckerman, Jerry M ^a,b   Qamar, Fozia ^c,d   Bono, Bartholomew R ^a,e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Med Ctr Ctrl Massachusetts U   (United States)

^e Bryn Mawr Medical Specialists Association   (United States)

Author keywords

Antimicrobials; Glycylcyclines; Ketolides; Macrolides; Review

Indexed keywords

ALPRAZOLAM; ASTEMIZOLE; ATORVASTATIN; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; COLCHICINE; DIHYDROERGOTAMINE; DISOPYRAMIDE; ERGOTAMINE; ERYTHROMYCIN; GLYCYLCYCLINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOLIDE; MACROLIDE; MEVINOLIN; MIDAZOLAM; PIMOZIDE; QUINIDINE; SILDENAFIL; SIMVASTATIN; TELITHROMYCIN; TERFENADINE; THEOPHYLLINE; TIGECYCLINE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE HEPATITIS; ACUTE RESPIRATORY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ATYPICAL MYCOBACTERIOSIS; BLURRED VISION; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; FATALITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HELICOBACTER INFECTION; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; MYASTHENIA GRAVIS; NAUSEA; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; QT INTERVAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN INFECTION; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 79958801909     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.03.012     Document Type: Review

References (213)

1. Omura S., Tsuzuki K., Sunazuka T., et al. Macrolides with gastrointestinal motor stimulating activity. J Med Chem 1987, 30(11):1941-1943.
2. Piscitelli S.C., Danziger L.H., Rodvold K.A. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992, 11(2):137-152.
3. Shain C.S., Amsden G.W. Telithromycin: the first of the ketolides. Ann Pharmacother 2002, 36(3):452-464.
4. Douthwaite S., Champney W.S. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001, 48(Suppl T1):1-8.
5. Champney W.S., Tober C.L. Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 1999, 38(6):342-348.
6. Frampton J.E., Curran M.P. Tigecycline. Drugs 2005, 65(18):2623-2635.
7. Sturgill M.G., Rapp R.P. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992, 26(9):1099-1108.
8. Hansen L.H., Mauvais P., Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999, 31(2):623-631.
9. Tait-Kamradt A., Clancy J., Cronan M., et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997, 41(10):2251-2255.
10. Ketek (telithromycin): briefing document for the FDA Anti-Infective Drug Products Advisory Committee Meeting, January 8, 2003. Gaithersburg, MD.
11. Bonnefoy A., Girard A.M., Agouridas C., et al. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997, 40(1):85-90.
12. Malhotra-Kumar S., Lammens C., Chapelle S., et al. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003. Emerg Infect Dis 2005, 11(6):939-942.
13. Al-Lahham A., Appelbaum P.C., van der Linden M., et al. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe. Antimicrob Agents Chemother 2006, 50(11):3897-3900.
14. Wolter N., Smith A.M., Farrell D.J., et al. Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. Antimicrob Agents Chemother 2008, 52(2):435-440.
15. Bergeron J., Ammirati M., Danley D., et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996, 40(9):2226-2228.
16. Hirata T., Saito A., Nishino K., et al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004, 48(6):2179-2184.
17. Dean C.R., Visalli M.A., Projan S.J., et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003, 47(3):972-978.
18. Peleg A.Y., Adams J., Paterson D.L. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51(6):2065-2069.
19. Abbott Laboratories. Biaxin (Clarithromycin): prescribing information. 2008;2008(12/23). Available at: Accessed August, 2009. http://www.rxabbott.com/pdf/biapi.PDF.
20. Guay D.R., Gustavson L.E., Devcich K.J., et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001, 23(4):566-577.
21. Foulds G., Luke D.R., Teng R., et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996, 37(Suppl C):37-44.
22. Chandra R., Liu P., Breen J.D., et al. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin. Clin Pharmacokinet 2007, 46(3):247-259.
23. Perret C., Lenfant B., Weinling E., et al. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 2002, 48(5):217-223.
24. Bhargava V., Lenfant B., Perret C., et al. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis 2002, 34(11):823-826.
25. Ferrero J.L., Bopp B.A., Marsh K.C., et al. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 1990, 18(4):441-446.
26. Liu P., Allaudeen H., Chandra R., et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007, 51(1):103-109.
27. Namour F., Wessels D.H., Pascual M.H., et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001, 45(1):170-175.
28. Muralidharan G., Fruncillo R.J., Micalizzi M., et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005, 49(4):1656-1659.
29. Muralidharan G., Micalizzi M., Speth J., et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49(1):220-229.
30. Meagher A.K., Ambrose P.G., Grasela T.H., et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005, 41(Suppl 5):S333-S340.
31. Foulds G., Shepard R.M., Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990, 25(Suppl A):73-82.
32. Fraschini F., Scaglione F., Pintucci G., et al. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother 1991, 27(Suppl A):61-65.
33. Rodvold K.A., Gotfried M.H., Danziger L.H., et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997, 41(6):1399-1402.
34. Muller-Serieys C., Soler P., Cantalloube C., et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 2001, 45(11):3104-3108.
35. Khair O.A., Andrews J.M., Honeybourne D., et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001, 47(6):837-840.
36. Conte J.E., Golden J.A., Kelly M.G., et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005, 25(6):523-529.
37. Rodvold K.A., Gotfried M.H., Cwik M., et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006, 58(6):1221-1229.
38. Sun H.K., Ong C.T., Umer A., et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005, 49(4):1629-1632.
39. Hardy D.J., Guay D.R., Jones R.N. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis 1992, 15(1):39-53.
40. Chu S.Y., Granneman G.R., Pichotta P.J., et al. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol 1993, 33(5):480-485.
41. Ballow C.H., Amsden G.W. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992, 26(10):1253-1261.
42. Westphal J.F. Macrolide -induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000, 50(4):285-295.
43. Mazzei T., Surrenti C., Novelli A., et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993, 31(Suppl E):57-63.
44. Zhanel G.G., Dueck M., Hoban D.J., et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001, 61(4):443-498.
45. Cantalloube C., Bhargava V., Sultan E., et al. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int J Antimicrob Agents 2003, 22(2):112-121.
46. Hoffmann M., DeMaio W., Jordan R.A., et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007, 35(9):1543-1553.
47. Tygacil (tigecycline) prescribing information. Available at: Accessed January, 2011. http://labeling.pfizer.com/showlabeling.aspx?id=491.
48. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing 2011, Eighteenth Informational Supplement, Clinical and Laboratory Standards Institute, Wayne (PA).
49. Whitman M.S., Tunkel A.R. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol 1992, 13(6):357-368.
50. Goldstein E.J., Citron D.M., Merriam C.V., et al. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 2003, 47(6):1963-1967.
51. Nagai K., Davies T.A., Ednie L.M., et al. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob Agents Chemother 2001, 45(11):3242-3245.
52. Shortridge V.D., Zhong P., Cao Z., et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob Agents Chemother 2002, 46(3):783-786.
53. Retsema J., Girard A., Schelkly W., et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987, 31(12):1939-1947.
54. Barry A.L., Fuchs P.C., Brown S.D. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998, 42(4):945-946.
55. Ubukata K., Iwata S., Sunakawa K. In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance. J Infect Chemother 2003, 9(3):221-226.
56. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001, 45(6):1721-1729.
57. Clark J.P., Langston E. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clin Proc 2003, 78(9):1113-1124.
58. Hardy D.J., Swanson R.N., Rode R.A., et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990, 34(7):1407-1413.
59. Barry A.L., Fuchs P.C., Brown S.D. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998, 42(8):2138-2140.
60. Fernandes P.B., Bailer R., Swanson R., et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 1986, 30(6):865-873.
61. Peters D.H., Clissold S.P. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992, 44(1):117-164.
62. Peters D.H., Friedel H.A., McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992, 44(5):750-799.
63. Slover C.M., Rodvold K.A., Danziger L.H. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother 2007, 41(6):965-972.
64. Garrison M.W., Mutters R., Dowzicky M.J. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009, 65(3):288-299.
65. Dowzicky M.J., Park C.H. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005-2007. Clin Ther 2008, 30(11):2040-2050.
66. Kresken M., Becker K., Siefert, et al. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens in Germany. Eur J Clin Microbiol Infect Dis 2011, [Epub ahead of print].
67. Castanheira M., Sader H.S., Deshpande L.M., et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52(2):570-573.
68. Hoban D.J., Bouchillon S.K., Dowzicky M.J. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 2007, 57(4):423-428.
69. Wang Y.F., Dowzicky M.J. In vitro activity of tigecycline and comparators on Acinetobacter spp. isoaltes collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial 2004 to 2008. Diagn Microbiol Infect Dis 2010, 68(1):73-79.
70. Darabi A., Hocquet D., Dowzicky M.J. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infec Dis 2010, 67(1):78-86.
71. Nagy E., Dowzicky M.J. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scan J Infect Dis 2010, 42(1):33-38.
72. Portier H., Filipecki J., Weber P., et al. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study. J Antimicrob Chemother 2002, 49(2):337-344.
73. Norrby S.R., Quinn J., Rangaraju M., et al. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis. Clin Microbiol Infect 2004, 10(7):615-623.
74. Quinn J., Ruoff G.E., Ziter P.S. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther 2003, 25(2):422-443.
75. McCarty J.M., Phillips A., Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993, 12(12):S122-S127.
76. Block S.L., Cifaldi M., Gu Y., et al. A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study. Clin Ther 2005, 27(6):786-794.
77. Ioannidis J.P., Contopoulos-Ioannidis D.G., Chew P., et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother 2001, 48(5):677-689.
78. Hoberman A., Dagan R., Leibovitz E., et al. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Infect Dis J 2005, 24(6):525-532.
79. Arguedas A., Emparanza P., Schwartz R.H., et al. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005, 24(2):153-161.
80. Adelglass J., Jones T.M., Ruoff G., et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998, 18(6):1255-1263.
81. Clifford K., Huck W., Shan M., et al. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis: Sinusitis Infection Study Group. Ann Otol Rhinol Laryngol 1999, 108(4):360-367.
82. Stefansson P., Jacovides A., Jablonicky P., et al. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998, 36(4):173-178.
83. Riffer E., Spiller J., Palmer R., et al. Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr Med Res Opin 2005, 21(1):61-70.
84. Murray J.J., Emparanza P., Lesinskas E., et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005, 133(2):194-200.
85. Henry D.C., Riffer E., Sokol W.N., et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003, 47(9):2770-2774.
86. Desrosiers M., Ferguson B., Klossek J.M., et al. Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis. Curr Med Res Opin 2008, 24(6):1691-1702.
87. Roos K., Tellier G., Baz M., et al. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J Infect 2005, 50(3):210-220.
88. Ferguson B.J., Guzzetta R.V., Spector S.L., et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004, 131(3):207-214.
89. Langtry H.D., Brogden R.N. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997, 53(6):973-1004.
90. Weiss K., Vanjaka A. An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther 2002, 24(12):2105-2122.
91. Adler J.L., Jannetti W., Schneider D., et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther 2000, 22(12):1410-1420.
92. Martinot J.B., Carr W.D., Cullen S., et al. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther 2001, 18(1):1-11.
93. Anzueto A., Fisher C.L., Busman T., et al. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther 2001, 23(1):72-86.
94. Gotfried M., Busman T.A., Norris S., et al. Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin 2007, 23(2):459-466.
95. Weiss L.R. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002, 24(9):1414-1425.
96. Wilson R., Schentag J.J., Ball P., et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002, 24(4):639-652.
97. Hoeffken G., Meyer H.P., Winter J., et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001, 95(7):553-564.
98. Gotfried M.H., Dattani D., Riffer E., et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002, 24(5):736-751.
99. Sokol W.N., Sullivan J.G., Acampora M.D., et al. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clin Ther 2002, 24(4):605-615.
100. Lode H., Aronkyto T., Chuchalin A.G., et al. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2004, 10(5):403-408.
101. Kinasewitz G., Wood R.G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991, 10(10):872-877.
102. Paris R., Confalonieri M., Dal Negro R., et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 2008, 20(1):77-86.
103. Drehobl M.A., De Salvo M.C., Lewis D.E., et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005, 128(4):2230-2237.
104. D'Ignazio J., Camere M.A., Lewis D.E., et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005, 49(10):4035-4041.
105. Contopoulos-Ioannidis D.G., Ioannidis J.P., Chew P., et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001, 48(5):691-703.
106. Panpanich R., Lerttrakarnnon P., Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2008, 1. CD001954.
107. Swanson R.N., Lainez-Ventosilla A., De Salvo M.C., et al. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat Respir Med 2005, 4(1):31-39.
108. Amsden G.W., Baird I.M., Simon S., et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003, 123(3):772-777.
109. Zervos M., Martinez F.J., Amsden G.W., et al. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 2007, 29(1):56-61.
110. Hagberg L., Carbon C., van Rensburg D.J., et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003, 97(6):625-633.
111. Pullman J., Champlin J., Vrooman P.S. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003, 57(5):377-384.
112. Mathers Dunbar L., Hassman J., Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004, 26(1):48-62.
113. Tellier G., Niederman M.S., Nusrat R., et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004, 54(2):515-523.
114. van Rensburg D.J., Fogarty C., Kohno S., et al. Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin. Chemotherapy 2005, 51(4):186-192.
115. Carbon C., van Rensburg D., Hagberg L., et al. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. Respir Med 2006, 100(4):577-585.
116. Fogarty C., de Wet R., Mandell L., et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005, 128(4):1980-1988.
117. Aubier M., Aldons P.M., Leak A., et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002, 96(11):862-871.
118. Carbon C. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults. Infection 2003, 31(5):308-317.
119. Vergis E.N., Indorf A., File T.M., et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000, 160(9):1294-1300.
120. Plouffe J., Schwartz D.B., Kolokathis A., et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia: the Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000, 44(7):1796-1802.
121. Feldman R.B., Rhew D.C., Wong J.Y., et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med 2003, 163(14):1718-1726.
122. Zervos M., Mandell L.A., Vrooman P.S., et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004, 3(5):329-336.
123. Frank E., Liu J., Kinasewitz G., et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002, 24(8):1292-1308.
124. Correa J.C., Badaro R., Bumroongkit C., et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003, 25(5):1453-1468.
125. Weiss K., Low D.E., Cortes L., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11(8):589-593.
126. Garcia Vazquez E., Mensa J., Martinez J.A., et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005, 24(3):190-195.
127. Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36(4):389-395.
128. Plouffe J.F., Breiman R.F., Fields B.S., et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003, 37(11):1475-1480.
129. Sahm D.F., Brown N.P., Draghi D.C., et al. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med 2008, 120(3 Suppl 1):8-15.
130. Jenkins S.G., Brown S.D., Farrell D.J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008, 7:1.
131. Critchley I.A., Brown S.D., Traczewski M.M., et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007, 51(12):4382-4389.
132. Jenkins S.G., Farrell D.J. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009, 15(8):1260-1264.
133. Farrell D.J., File T.M., Jenkins S.G. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol 2007, 45(2):290-293.
134. Sahm D.F., Brown N.P., Thornsberry C., et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 2008, 120(3 Suppl 1):16-24.
135. Rantala M., Haanpera-Heikkinen M., Lindgren M., et al. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob Agents Chemother 2006, 50(5):1855-1858.
136. Lau Y.J., Hsueh P.R., Liu Y.C., et al. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 2006, 12(2):130-135.
137. Rowe B.H., Campbell S.G., Boudreaux E.D., et al. Community-acquired pneumonia in North American emergency departments: drug resistance and treatment success with clarithromycin. Acad Emerg Med 2007, 14(7):607-615.
138. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35(5):556-564.
139. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
140. Lau C.Y., Qureshi A.K. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002, 29(9):497-502.
141. Pitsouni E., Iavazzo C., Athanasiou S., et al. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007, 30(3):213-221.
142. Workowski K.A., Berman S.M. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR-12):1-110.
143. Skerk V., Schonwald S., Krhen I., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003, 21(5):457-462.
144. Skerk V., Krhen I., Lisic M., et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004, 24(2):188-191.
145. Handsfield H.H., Dalu Z.A., Martin D.H., et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea: Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994, 21(2):107-111.
146. Bevan C.D., Ridgway G.L., Rothermel C.D. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003, 31(1):45-54.
147. Bai Z.G., Yang K.H., Liu Y.L., et al. Azithromycin vs. benzathine penicillin G for early syphilis: a meta-analysis of randomized clinical trials. Int J STD AIDS 2008, 19(4):217-221.
148. Riedner G., Rusizoka M., Todd J., et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005, 353(12):1236-1244.
149. Hook E.W., Behets F., Van Damme K., et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010, 201(11):1729-1735.
150. Su JR, Hook E, Kenney K, et al. Prevalence of the 23S rRNA point mutation in Treponema pallidum in the United States and Associated Factors, 2006-2008. 18th International Society for Sexually Transmitted Diseases Research, #OS1.11.03. London, England: June 2009.
151. Chey W.D., Wong B.C., Practice Parameters Committee of the American College of Gastroenterology American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102(8):1808-1825.
152. Suerbaum S., Michetti P. Helicobacter pylori infection. N Engl J Med 2002, 347(15):1175-1186.
153. Vergara M., Vallve M., Gisbert J.P., et al. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003, 18(6):647-654.
154. Gene E., Calvet X., Azagra R., et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003, 17(9):1137-1143.
155. Laheij R.J., Rossum L.G., Jansen J.B., et al. Evaluation of treatment regimens to cure Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 1999, 13(7):857-864.
156. Calvet X., Garcia N., Lopez T., et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000, 14(5):603-609.
157. Paoluzi P., Iacopini F., Crispino P., et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006, 11(6):562-568.
158. Vaira D., Zullo A., Vakil N., et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007, 146(8):556-563.
159. Zullo A., De Francesco V., Hassan C., et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007, 56(10):1353-1357.
160. Jafri N.S., Hornung C.A., Howden C.W. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008, 148(12):923-931.
161. Meyer J.M., Silliman N.P., Wang W., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002, 136(1):13-24.
162. Duck W.M., Sobel J., Pruckler J.M., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004, 10(6):1088-1094.
163. De Francesco V., Margiotta M., Zullo A., et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007, 59(4):783-785.
164. McMahon B.J., Hennessy T.W., Bensler J.M., et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003, 139(6):463-469.
165. Lee J.H., Shin J.H., Roe I.H., et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005, 49(4):1600-1603.
166. Dore M.P., Leandro G., Realdi G., et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000, 45(1):68-76.
167. Havlir D.V., Dube M.P., Sattler F.R., et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both: California Collaborative Treatment Group. N Engl J Med 1996, 335(6):392-398.
168. Benson C.A., Williams P.L., Cohn D.L., et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000, 181(4):1289-1297.
169. Kaplan J.E., Benson C., Holmes K.K., et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-Exposed and HIV-Infected Children-Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009, 58(RR-11):1-166.
170. Shafran S.D., Singer J., Zarowny D.P., et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996, 335(6):377-383.
171. Cohn D.L., Fisher E.J., Peng G.T., et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 1999, 29(1):125-133.
172. Benson C.A., Williams P.L., Currier J.S., et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003, 37(9):1234-1243.
173. Dunne M., Fessel J., Kumar P., et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000, 31(5):1245-1252.
174. Ward T.T., Rimland D., Kauffman C., et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 1998, 27(5):1278-1285.
175. Wallace R.J., Brown B.A., Griffith D.E., et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994, 149(5):1335-1341.
176. Griffith D.E., Brown B.A., Girard W.M., et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996, 23(5):983-989.
177. Griffith D.E., Brown B.A., Murphy D.T., et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998, 178(1):121-126.
178. Griffith D.E., Brown B.A., Cegielski P., et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000, 30(2):288-292.
179. Lam P.K., Griffith D.E., Aksamit T.R., et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 173(11):1283-1289.
180. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
181. Sacchidanand S., Penn R.L., Embil J.M., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9(5):251-261.
182. Breedt J., Teras J., Gardovskis J., et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49(11):4658-4666.
183. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-S353.
184. Florescu I., Beuran M., Dimov R., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(Suppl 1):i17-i28.
185. Fomin P., Beuran M., Gradauskas A., et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005, 3(1):35-47.
186. Oliva M.E., Rekha A., Yellin A., et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005, 5:88. [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
187. Babinchak T., Ellis-Grosse E., Dartois N., et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354-S367.
188. Bergallo C., Jasovich A., Teglia O., et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009, 63(1):52-61.
189. Tanaseanu C., Bergallo C., Teglia O., et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61(3):329-338.
190. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62(5):895-904.
191. Vasilev K., Reshedko G., Orasan R., et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008, 62(Suppl 1):i29-i40.
192. Gallagher J.C., Rouse H.M. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008, 42(9):1188-1194.
193. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62(1):45-55.
194. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63(4):775-780.
195. Nieman R.B., Sharma K., Edelberg H., et al. Telithromycin and myasthenia gravis. Clin Infect Dis 2003, 37(11):1579.
196. Anthony K.B., Fishman N.O., Linkin D.R., et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46(4):567-570.
197. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991, 91(3):40S-45S.
198. Garey K.W., Amsden G.W. Intravenous azithromycin. Ann Pharmacother 1999, 33(2):218-228.
199. Guay D.R., Patterson D.R., Seipman N., et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993, 8(5):350-364.
200. Ketek (telithromycin) tablets: prescribing information. 2007;2008(November, 28).
201. Demolis J.L., Vacheron F., Cardus S., et al. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 2003, 73(3):242-252.
202. Ross D.B. The FDA and the case of Ketek. N Engl J Med 2007, 356(16):1601-1604.
203. Brinker A.D., Wassel R.T., Lyndly J., et al. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology 2009, 49:250-257.
204. Clay K.D., Hanson J.S., Pope S.D., et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006, 144(6):415-420.
205. Perrot X., Bernard N., Vial C., et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006, 67(12):2256-2258.
206. U.S. Food and Drug Administration. Telithromycin (marketed as Ketek) Information. 2007;2008(12/22).
207. Gilson M., Moachon L., Jeanne L., et al. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand J Infect Dis 2008, 40(3):1-3.
208. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001, 18(Suppl 1):S71-S76.
209. Amsden G.W. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995, 29(9):906-917.
210. Gomes T., Mamdani M.M., Juurlink D.N. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther 2009, 86(4):383-386.
211. Zimmerman J.J., Harper D.M., Matschke K., et al. Absence of an interaction between tigecycline and digoxin in healthy men. Pharmacotherapy 2007, 27(6):835-844.
212. Zimmerman J.J., Raible D.G., Harper D.M., et al. Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy 2008, 28(7):895-905.
213. FDA. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at: Accessed March 23, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.